默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MRK 默沙东

交易中 05-27 10:58:01 EDT

121.47

+1.75

+1.46%

最高122.37	最低119.78	成交量156.58万
今开120.00	昨收119.72	日振幅2.16%
总市值3,015亿	流通市值3,015亿	总股本24.82亿
成交额1.90亿	换手率0.06%	流通股本24.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MRK","market":"US","secType":"STK","nameCN":"默沙东","latestPrice":121.47,"timestamp":1779893881062,"preClose":119.72,"halted":0,"volume":1565812,"delay":0,"changeRate":0.014617440694954895,"floatShares":2482022536,"shares":2482022536,"eps":3.575809,"marketStatus":"交易中","change":1.75,"latestTime":"05-27 10:58:01 EDT","open":120,"high":122.37,"low":119.78,"amount":190454426.65412,"amplitude":0.021634,"askPrice":121.52,"askSize":106,"bidPrice":121.46,"bidSize":101,"shortable":3,"etf":0,"ttmEps":3.575809,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1779912000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-745790400000,"exchange":"NYSE","adjPreClose":119.72,"dividendRate":0.027003,"preHourTrading":{"tag":"盘前","latestPrice":119.74,"preClose":119.72,"latestTime":"09:29 EDT","volume":1818,"amount":217997.52534,"timestamp":1779888543359,"change":0.02,"changeRate":0.000167,"amplitude":0.016811},"postHourTrading":{"tag":"盘后","latestPrice":120.25,"preClose":119.72,"latestTime":"19:55 EDT","volume":459099,"amount":54964673.4498,"timestamp":1779839724252,"change":0.53,"changeRate":0.004427,"amplitude":0.004594},"volumeRatio":0.702218,"impliedVol":0.2601,"impliedVolPercentile":0.0478},"requestUrl":"/m/hq/s/MRK","defaultTab":"news","newsList":[{"id":"1172241710","title":"Adcendo Aps：双方公司保留各自化合物全部商业权利，涵盖单药及联合疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1172241710","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172241710?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:09","pubTimestamp":1779793787,"startTime":"0","endTime":"0","summary":"Adcendo Aps宣布，合作双方将各自保留其相关化合物的全部商业化权益，这些权益范围包括作为单一疗法使用，或与其他疗法进行联合应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035773651.USD","LU1934455277.USD","LU1699723380.USD","SG9999013999.USD","LU2112291526.USD","LU2461242641.AUD","BK4585","SG9999002232.USD","LU1066051498.USD","LU1934455863.HKD","LU2023250504.SGD","SG9999001176.USD","LU1917777945.USD","LU0203345920.USD","LU2125154778.USD","LU0648001328.SGD","LU0965508806.USD","LU2360032135.SGD","SG9999002224.SGD","SG9999001440.SGD","LU0965509010.AUD","SG9999014542.SGD","SG9999015358.SGD","LU0058720904.USD","MRK","IE00B1BXHZ80.USD","LU0098860793.USD","LU2361044865.SGD","LU1430594728.SGD","LU2468319806.SGD","LU0234572021.USD","LU2491049909.HKD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1989772923.USD","LU0070302665.USD","IE00BBT3K403.USD","LU0203347892.USD","LU2324357040.USD","LU0106261372.USD","LU0965509283.SGD","SGXZ57979304.SGD","LU1974910355.USD","IE00BLSP4452.SGD","LU1066053197.SGD","BK4007","LU0985320562.USD","LU2125909593.SGD","LU2491050071.SGD","LU0942090050.USD","LU0265550359.USD","LU1585245621.USD","BK4534","LU1037948541.HKD","IE0009355771.USD","LU2357627491.SGD","LU0211331839.USD","LU1291159041.SGD","LU0266013472.USD","IE00BSNM7G36.USD","LU1037948897.HKD","LU2361044949.HKD","LU0208291251.USD","LU2361045086.USD","SG9999015341.SGD","LU0130517989.USD","LU0130102774.USD","LU0432979614.USD","LU1201861249.SGD","LU1066051811.HKD","LU1934455194.USD","LU0320765646.SGD","LU0868494708.USD","BK4588","LU1989772840.SGD","LU0861579265.USD","LU0006306889.USD","LU0477156953.USD","LU0265550946.USD","LU1989771016.USD","BK4533","IE00B4R5TH58.HKD","LU1061106388.HKD","LU1571399168.USD","IE00BN8TJ469.HKD","LU0122379950.USD","LU1162221912.USD","SG9999014567.USD","LU2125909247.SGD","LU0980610538.SGD","LU1066051225.USD","LU0859254822.USD","LU2023250843.SGD","BK4550","LU1057294990.SGD","LU1116320901.HKD","LU0320765489.SGD","LU1093756325.SGD","LU1093756168.USD","LU1069347547.HKD","LU1929549753.HKD","LU2089984988.USD","IE00B2B36J28.USD","BK4559","LU0238689110.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","LU2433249047.HKD","IE00BJT1NW94.SGD","LU0868494617.USD","SG9999001176.SGD","LU2491050154.USD","LU1941712348.USD","LU1116320737.USD","LU1941712264.USD","BK4516","LU2125154935.USD","IE000M9KFDE8.USD","LU0965509101.SGD","LU1923622614.USD","LU0289739699.SGD","SG9999014575.USD","LU2106854487.HKD","LU1023059063.AUD","IE00BLSP4239.USD","SG9999014559.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142473894","title":"Adcendo Aps与默沙东达成临床合作与供应协议，共同评估Adce-T02与Keytruda联合疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1142473894","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142473894?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:08","pubTimestamp":1779793708,"startTime":"0","endTime":"0","summary":"Adcendo Aps宣布与默沙东（Merck）达成一项临床合作与供应协议。双方将携手评估其候选药物Adce-T02与默沙东的抗PD-1疗法Keytruda（帕博利珠单抗）联合使用的潜力。\n此项合作旨在探索联合用药方案在特定适应症中的疗效与安全性。通过结合Adcendo的靶向疗法与默沙东已确立的免疫肿瘤药物，双方期望能开发出更具创新性的癌症治疗策略。协议的达成标志着Adcendo在推进其研发管线的战略布局上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU2125154778.USD","LU2125154935.USD","LU2491049909.HKD","LU1201861249.SGD","LU0234572021.USD","LU1035773651.USD","SG9999002232.USD","SG9999001176.USD","LU1989771016.USD","BK4588","LU2361044949.HKD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","IE00B2B36J28.USD","LU0859254822.USD","LU2324357040.USD","LU2361044865.SGD","LU0432979614.USD","LU0965509283.SGD","LU1291159041.SGD","LU2106854487.HKD","LU0965509010.AUD","LU0006306889.USD","LU2023250504.SGD","LU2461242641.AUD","SG9999015358.SGD","IE0009355771.USD","BK4007","IE0002141913.USD","SG9999002224.SGD","BK4516","LU1923622614.USD","LU0211331839.USD","LU0266013472.USD","LU2491050154.USD","LU0130517989.USD","LU0058720904.USD","LU0477156953.USD","LU0098860793.USD","LU2357627491.SGD","LU1023059063.AUD","LU1983299246.USD","LU1066051498.USD","LU1929549753.HKD","LU1699723380.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU2468319806.SGD","SG9999001176.SGD","LU1093756168.USD","IE00BJT1NW94.SGD","LU2112291526.USD","LU1430594728.SGD","SG9999014567.USD","LU2360032135.SGD","LU2491050071.SGD","LU0070302665.USD","LU0265550359.USD","BK4534","LU2023250843.SGD","BK4559","IE00BBT3K403.USD","SG9999014542.SGD","LU0868494617.USD","BK4533","LU0965509101.SGD","IE00B1BXHZ80.USD","SG9999014575.USD","SG9999015341.SGD","IE00BJJMRZ35.SGD","LU1037948897.HKD","LU2125909593.SGD","LU1066051811.HKD","LU1934455277.USD","LU0208291251.USD","IE00BFTCPJ56.SGD","LU0942090050.USD","LU2433249047.HKD","LU0265550946.USD","LU0965508806.USD","BK4585","LU0861579265.USD","LU2125909247.SGD","IE00BLSP4239.USD","LU0985320562.USD","LU1989772923.USD","LU1917777945.USD","SGXZ57979304.SGD","LU1116320737.USD","LU1162221912.USD","LU0980610538.SGD","LU2361045086.USD","LU0130102774.USD","LU1571399168.USD","LU1934455863.HKD","SG9999013999.USD","LU0868494708.USD","LU1974910355.USD","LU1093756325.SGD","MRK","LU0203345920.USD","LU0289739699.SGD","LU1057294990.SGD","LU1037948541.HKD","LU1989772840.SGD","LU0320765646.SGD","LU0106261372.USD","LU0203347892.USD","LU1069347547.HKD","IE00BN8TJ469.HKD","LU1061106388.HKD","LU1934455194.USD","LU1066051225.USD","LU2089984988.USD","LU1941712264.USD","SG9999014559.SGD","LU0122379950.USD","LU1066053197.SGD","LU0320765489.SGD","LU1116320901.HKD","LU0648001328.SGD","LU1941712348.USD","LU0238689110.USD","IE00B4R5TH58.HKD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193611796","title":"Adcendo Aps达成协议：公司将资助1B期临床试验，默沙东将提供帕博利珠单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=1193611796","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193611796?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:08","pubTimestamp":1779793701,"startTime":"0","endTime":"0","summary":"根据一项新达成的协议，Adcendo Aps公司将负责资助一项1B期临床试验，而默沙东将为此项试验提供其药物帕博利珠单抗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2461242641.AUD","SG9999014567.USD","IE0002141913.USD","LU0265550359.USD","LU1989772840.SGD","LU0265550946.USD","LU1430594728.SGD","LU2324357040.USD","LU0320765646.SGD","LU0130517989.USD","LU1116320901.HKD","LU1974910355.USD","LU1035773651.USD","LU0208291251.USD","LU0098860793.USD","LU0965509101.SGD","LU1934455277.USD","SG9999013999.USD","LU0868494708.USD","LU0106261372.USD","LU1941712264.USD","LU1066051225.USD","BK4516","LU1057294990.SGD","LU2106854487.HKD","IE00BLSP4452.SGD","LU1066051498.USD","LU0965509283.SGD","SG9999001176.SGD","LU1934455863.HKD","LU1989771016.USD","IE00B1BXHZ80.USD","LU1929549753.HKD","IE00B4R5TH58.HKD","SG9999014542.SGD","LU0432979614.USD","BK4585","BK4007","LU2491050154.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU2125154778.USD","LU2125154935.USD","IE00BJJMRZ35.SGD","LU2112291526.USD","LU0985320562.USD","LU0266013472.USD","SG9999015341.SGD","IE00B2B36J28.USD","LU2433249047.HKD","LU2089984988.USD","LU1201861249.SGD","LU0965509010.AUD","LU1037948897.HKD","LU1116320737.USD","LU2023250843.SGD","LU0965508806.USD","SGXZ57979304.SGD","LU2361044865.SGD","SG9999015358.SGD","MRK","SG9999001440.SGD","LU1093756168.USD","LU1934455194.USD","LU1162221912.USD","LU2125909247.SGD","LU0980610538.SGD","LU2023250504.SGD","IE0009355771.USD","BK4559","IE00BSNM7G36.USD","LU0130102774.USD","LU1989772923.USD","LU1069347547.HKD","LU2361045086.USD","LU0203347892.USD","LU1585245621.USD","LU1066051811.HKD","LU1699723380.USD","SG9999002224.SGD","LU1066053197.SGD","LU2468319806.SGD","LU2360032135.SGD","LU0234572021.USD","LU0477156953.USD","LU1923622614.USD","SG9999014559.SGD","LU1941712348.USD","LU0861579265.USD","BK4534","LU0070302665.USD","LU2125909593.SGD","LU2491050071.SGD","LU1093756325.SGD","LU0320765489.SGD","LU0942090050.USD","LU2361044949.HKD","SG9999002232.USD","LU0211331839.USD","LU2491049909.HKD","LU1983299246.USD","IE00BBT3K403.USD","IE00BJT1NW94.SGD","LU0122379950.USD","LU1023059063.AUD","LU1037948541.HKD","BK4533","SG9999014575.USD","IE00BLSP4239.USD","LU1571399168.USD","BK4550","LU0868494617.USD","LU2357627491.SGD","LU1061106388.HKD","LU0006306889.USD","LU0238689110.USD","IE00BN8TJ469.HKD","LU0058720904.USD","IE000M9KFDE8.USD","LU1917777945.USD","LU0203345920.USD","BK4588","SG9999001176.USD","LU0648001328.SGD","LU0289739699.SGD","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637343626","title":"默沙东K药联合Padcev获欧盟CHMP积极意见，用于治疗顺铂不耐受肌层浸润性膀胱癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2637343626","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637343626?lang=zh_cn&edition=full","pubTime":"2026-05-22 23:28","pubTimestamp":1779463680,"startTime":"0","endTime":"0","summary":"默沙东于5月22日宣布，欧洲药品管理局人用药品委员会已采纳积极意见，推荐批准KEYTRUDA联合Padcev用于治疗顺铂不耐受的可切除肌层浸润性膀胱癌成人患者，作为新辅助治疗并在根治性膀胱切除术后继续作为辅助治疗。该试验在顺铂不耐受或拒绝接受含顺铂化疗的MIBC患者中，比较了围手术期K药联合Padcev治疗与单纯手术的效果。欧洲委员会预计将在2026年第三季度前做出最终审批决定。目前该联合疗法已在美国获得批准用于相同适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyuwef7534467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999001440.SGD","LU0130517989.USD","LU0106261372.USD","LU2089984988.USD","LU0965509283.SGD","LU0208291251.USD","LU2125154778.USD","LU1066051811.HKD","SG9999015341.SGD","LU0238689110.USD","LU0289739699.SGD","LU1571399168.USD","LU2461242641.AUD","IE00BFTCPJ56.SGD","LU1162221912.USD","LU0234572021.USD","IE00B2B36J28.USD","BK4585","LU0098860793.USD","SG9999014575.USD","LU2023250504.SGD","IE00B4R5TH58.HKD","LU1066051498.USD","BK4534","LU1023059063.AUD","LU1430594728.SGD","LU2106854487.HKD","SG9999001176.SGD","LU1069347547.HKD","LU2361044949.HKD","LU2360032135.SGD","LU0203345920.USD","SG9999014559.SGD","LU2361044865.SGD","LU0965508806.USD","LU1037948897.HKD","LU2491049909.HKD","LU0122379950.USD","SGXZ57979304.SGD","LU0320765489.SGD","LU0211331839.USD","IE00BLSP4239.USD","IE0009355771.USD","LU1093756168.USD","LU1116320737.USD","LU0985320562.USD","LU1941712348.USD","LU0070302665.USD","LU0859254822.USD","LU1066053197.SGD","LU1989771016.USD","IE00BJT1NW94.SGD","LU0006306889.USD","IE00BJJMRZ35.SGD","LU2433249047.HKD","LU1116320901.HKD","LU0861579265.USD","IE0002141913.USD","LU2125154935.USD","IE00BN8TJ469.HKD","LU0130102774.USD","LU1585245621.USD","LU0965509010.AUD","BK4550","LU1093756325.SGD","IE00BBT3K403.USD","SG9999013999.USD","LU0266013472.USD","BK4559","LU1934455277.USD","IE000M9KFDE8.USD","LU0980610538.SGD","SG9999014567.USD","LU0320765646.SGD","LU0058720904.USD","LU0432979614.USD","LU1989772923.USD","LU0265550946.USD","LU1929549753.HKD","LU1035773651.USD","LU0265550359.USD","LU1061106388.HKD","LU1291159041.SGD","LU0965509101.SGD","LU1923622614.USD","LU2324357040.USD","MRK","IE00BLSP4452.SGD","LU2125909593.SGD","LU1057294990.SGD","LU2361045086.USD","LU1699723380.USD","LU1201861249.SGD","LU1983299246.USD","LU2357627491.SGD","SG9999015358.SGD","LU2112291526.USD","SG9999001176.USD","BK4007","IE00B1BXHZ80.USD","SG9999002224.SGD","LU0868494708.USD","LU0868494617.USD","BK4533","LU2491050154.USD","SG9999002232.USD","BK4516","LU2468319806.SGD","LU1934455194.USD","LU1066051225.USD","LU2023250843.SGD","SG9999014542.SGD","LU1941712264.USD","LU0203347892.USD","LU2125909247.SGD","IE00BSNM7G36.USD","LU0942090050.USD","LU1037948541.HKD","LU1917777945.USD","LU1934455863.HKD","BK4588","LU1974910355.USD","LU1989772840.SGD","LU2491050071.SGD","LU0648001328.SGD","LU0477156953.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125632815","title":"默沙东股价因癌症数据上涨，为何这家制药商不会仅依赖一款“王牌药物”？","url":"https://stock-news.laohu8.com/highlight/detail?id=1125632815","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125632815?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:57","pubTimestamp":1779461871,"startTime":"0","endTime":"0","summary":"默沙东正试图缓解2028年即将到来的冲击，届时Keytruda的核心专利保护将开始到期。作为肿瘤治疗领域公认的“神药”，Keytruda是有史以来销量最高的药物之一，因此其失去市场独占权将对公司构成重大不利影响。2022年，默沙东与这家中国药企达成独家授权协议，共同建立用于癌症治疗的ADC产品组合。周五股价上涨还受到监管层面积极进展的进一步推动。","market":"us","thumbnail":"https://community-static.tradeup.com/news/46fe1aebdcc6399ee66a93a44835bba6","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/46fe1aebdcc6399ee66a93a44835bba6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1524d98f25a887386dd8f38c500227b6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"默沙东股价因癌症数据上涨，为何这家制药商不会仅依赖一款“王牌药物”？","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637531064","title":"默沙东(MRK)与科伦联合研发取得突破 肺癌新药临床效果亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2637531064","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637531064?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:14","pubTimestamp":1779459290,"startTime":"0","endTime":"0","summary":"金吾财讯 | 科伦生物周四披露重要临床进展，企业与默沙东合作研发的抗体药物偶联物，相关疗法在晚期肺癌临床试验中，疗效表现超越常规抗 PD-1 治疗方案。公开试验摘要显示，默沙东 2022 年取得大中华区以外权益的 sac-TMT，可显著降低 65% 疾病进展与死亡风险，数据具备统计学价值。安全性层面两组差异明显，联合用药重度不良反应发生率为 55%，单药组仅 31%。两类药物停药相关不良反应占比分别为 4% 与 5%，单药停药比例同样为 5%。","market":"us","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1524d98f25a887386dd8f38c500227b6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001440.SGD","LU0130517989.USD","LU0106261372.USD","LU2089984988.USD","002422","LU0965509283.SGD","LU0208291251.USD","LU2125154778.USD","LU2148510915.USD","LU1934453819.USD","LU1066051811.HKD","SG9999015341.SGD","LU0238689110.USD","LU0289739699.SGD","LU1571399168.USD","LU2461242641.AUD","IE00BFTCPJ56.SGD","LU1162221912.USD","LU0234572021.USD","IE00B2B36J28.USD","BK4585","LU0098860793.USD","SG9999014575.USD","LU2023250504.SGD","BK0060","IE00B4R5TH58.HKD","LU1066051498.USD","BK4534","LU1023059063.AUD","LU1430594728.SGD","LU2106854487.HKD","SG9999001176.SGD","LU1069347547.HKD","LU2361044949.HKD","BK0239","LU2360032135.SGD","LU0203345920.USD","SG9999014559.SGD","LU2361044865.SGD","LU0965508806.USD","LU1037948897.HKD","LU2491049909.HKD","LU0122379950.USD","SGXZ57979304.SGD","LU0320765489.SGD","LU0211331839.USD","IE00BLSP4239.USD","IE0009355771.USD","LU1093756168.USD","LU1116320737.USD","LU0985320562.USD","LU1941712348.USD","LU0070302665.USD","LU0859254822.USD","LU1066053197.SGD","LU1989771016.USD","IE00BJT1NW94.SGD","LU0006306889.USD","LU1979443071.USD","IE00BJJMRZ35.SGD","LU2433249047.HKD","LU1116320901.HKD","LU0861579265.USD","IE0002141913.USD","LU2125154935.USD","IE00BN8TJ469.HKD","LU0130102774.USD","LU1585245621.USD","LU0965509010.AUD","BK4550","LU1093756325.SGD","IE00BBT3K403.USD","SG9999013999.USD","LU0266013472.USD","BK4559","LU1934455277.USD","IE000M9KFDE8.USD","LU0980610538.SGD","SG9999014567.USD","LU0320765646.SGD","LU0058720904.USD","LU0432979614.USD","LU1064130708.USD","LU1989772923.USD","LU0265550946.USD","LU1929549753.HKD","LU1035773651.USD","LU0265550359.USD","LU1061106388.HKD","LU1291159041.SGD","LU0965509101.SGD","LU1064131003.USD","LU1923622614.USD","LU2324357040.USD","MRK","IE00BLSP4452.SGD","LU2125909593.SGD","LU1057294990.SGD","LU2361045086.USD","LU1699723380.USD","LU1201861249.SGD","LU1983299246.USD","LU2357627491.SGD","SG9999015358.SGD","LU2112291526.USD","SG9999001176.USD","BK4007","IE00B1BXHZ80.USD","SG9999002224.SGD","LU0868494708.USD","LU0868494617.USD","BK4533","LU2491050154.USD","SG9999002232.USD","BK4516","LU2468319806.SGD","LU1934455194.USD","LU1066051225.USD","LU2023250843.SGD","SG9999014542.SGD","LU1941712264.USD","LU0203347892.USD","LU2125909247.SGD","IE00BSNM7G36.USD","LU0942090050.USD","LU1037948541.HKD","LU1917777945.USD","LU1934455863.HKD","BK4588","LU1974910355.USD","LU1989772840.SGD","LU2491050071.SGD","LU0648001328.SGD","LU0477156953.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186797770","title":"异动解读 | 肺癌联合疗法III期试验成功，默沙东盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186797770","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186797770?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:13","pubTimestamp":1779459210,"startTime":"0","endTime":"0","summary":"默沙东今日盘中股价大涨5.01%，引起了市场的高度关注。该联合疗法达到了试验的主要终点，与单用Keytruda相比，显著降低了患者疾病进展或死亡的风险约65%，这被分析师评价为“极具鼓舞性”的数据，并被视为肺癌治疗领域的一项重要进展。此外，默沙东近期在其他肿瘤管线也传出利好，包括Keytruda联合Padcev用于膀胱癌的疗法获得欧盟监管机构的积极意见，以及其TROP2靶向ADC在子宫内膜癌的III期试验中达到双重主要终点。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1524d98f25a887386dd8f38c500227b6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152994441","title":"默沙东癌症疗法获积极进展 市场关注度升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1152994441","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152994441?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:59","pubTimestamp":1779458348,"startTime":"0","endTime":"0","summary":"美国临床肿瘤学会发布的一项研究摘要，被摩根大通分析师评价为“极具鼓舞性”。这项名为sac-TMT的靶向化疗方案由默沙东与中国生物科技公司科伦博泰联合开发。分析师指出：“在联合患者群体中，sac-TMT将死亡或疾病进展风险降低了65%。”不过他们也补充说明，该药物的对照对象是默沙东自身的Keytruda单药疗法，而此方案并非全球多数地区的标准治疗方案，这使直接比较变得复杂。尽管如此，分析师强调：“数据本身依然坚实……并持续降低了sac-TMT的研发风险。”受此消息提振，默沙东股价上涨4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1524d98f25a887386dd8f38c500227b6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051225.USD","SG9999001440.SGD","LU0965509101.SGD","LU0058720904.USD","SG9999014559.SGD","SG9999015358.SGD","SG9999015341.SGD","LU1934455277.USD","BK4534","LU2361044949.HKD","SG9999014542.SGD","IE00B4R5TH58.HKD","LU2433249047.HKD","LU0985320562.USD","SG9999014567.USD","BK4516","LU0320765489.SGD","BK4533","LU0208291251.USD","LU2106854487.HKD","LU0868494617.USD","LU0965509010.AUD","BK4559","LU1037948897.HKD","SG9999001176.SGD","LU2023250504.SGD","LU1585245621.USD","LU1069347547.HKD","LU1291159041.SGD","LU0203345920.USD","IE0002141913.USD","SG9999013999.USD","LU2324357040.USD","LU1934455194.USD","LU0868494708.USD","SGXZ57979304.SGD","LU1116320901.HKD","LU1989772923.USD","LU1571399168.USD","LU2125909247.SGD","BK4550","LU0211331839.USD","LU2125909593.SGD","LU0106261372.USD","LU1066051498.USD","LU0861579265.USD","LU2491050071.SGD","LU1941712348.USD","LU1923622614.USD","SG9999001176.USD","LU0432979614.USD","LU1941712264.USD","IE00BLSP4452.SGD","IE0009355771.USD","IE00BN8TJ469.HKD","LU1201861249.SGD","LU1974910355.USD","LU2361044865.SGD","LU1162221912.USD","LU1093756168.USD","IE00B2B36J28.USD","LU2491050154.USD","SG9999014575.USD","LU0006306889.USD","LU0203347892.USD","LU1989771016.USD","LU1035773651.USD","LU1934455863.HKD","LU2023250843.SGD","LU2360032135.SGD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU0289739699.SGD","LU1917777945.USD","LU1037948541.HKD","LU1699723380.USD","SG9999002232.USD","BK4585","LU0477156953.USD","IE00BJJMRZ35.SGD","LU0265550359.USD","LU0320765646.SGD","LU1066053197.SGD","LU0965509283.SGD","LU0238689110.USD","IE00B1BXHZ80.USD","LU0648001328.SGD","LU1057294990.SGD","IE00BLSP4239.USD","BK4588","MRK","IE000M9KFDE8.USD","LU1061106388.HKD","LU2461242641.AUD","LU1929549753.HKD","LU1066051811.HKD","LU0942090050.USD","LU0965508806.USD","LU2125154935.USD","LU1983299246.USD","LU1989772840.SGD","IE00BBT3K403.USD","IE00BSNM7G36.USD","LU2491049909.HKD","LU0098860793.USD","LU1093756325.SGD","LU2125154778.USD","LU1430594728.SGD","SG9999002224.SGD","IE00BJT1NW94.SGD","LU0130102774.USD","LU2089984988.USD","LU0980610538.SGD","LU1023059063.AUD","LU0070302665.USD","LU0122379950.USD","LU0265550946.USD","LU0859254822.USD","BK4007","LU2361045086.USD","LU0266013472.USD","LU2357627491.SGD","LU1116320737.USD","LU2112291526.USD","LU2468319806.SGD","LU0130517989.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108440543","title":"异动解读｜默沙东盘中上涨4.5%，TROP2 ADC子宫内膜癌III期试验达双重主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1108440543","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108440543?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:33","pubTimestamp":1779456791,"startTime":"0","endTime":"0","summary":"5月22日，默沙东盘中上涨4.5%，报120.93美元/股，成交额1798.22万美元。消息面上，默沙东宣布其与科伦博泰合作开发的TROP2靶向抗体偶联药物Sacituzumab Tirumotecan，在针对晚期或复发性子宫内膜癌患者的全球III期TroFuse-005试验中，达到了总生存期与无进展生存期双重主要终点，同时达到客观缓解率次要终点。TroFuse-005是首个在该类患者中相较化疗同时实现OS和PFS统计学显著改善的全球III期试验，进一步验证了默沙东在ADC管线上的布局潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637631481","title":"默沙东肺癌联合疗法III期研究成功，肿瘤进展风险降低65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637631481","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637631481?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:34","pubTimestamp":1779453240,"startTime":"0","endTime":"0","summary":"默沙东于5月21日宣布，其与科伦博泰合作开发的抗体偶联药物sacituzumab tirumotecan联合Keytruda，在治疗非小细胞肺癌的III期研究中取得积极结果。受此消息提振，默沙东股价当日上涨逾3%。　　研究数据显示，与Keytruda单药治疗相比，sac-TMT联合疗法可将患者的疾病进展或死亡风险显著降低65%。联合治疗组的客观缓解率达70.2%，而Keytruda单药组为42%。目前该联合疗法已在中国提交上市申请并获优先审评资格，详细数据将在2026年ASCO年会上公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyurwe8323384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","SG9999014542.SGD","LU0965509101.SGD","LU2125154778.USD","LU0289739699.SGD","SG9999001176.SGD","LU0006306889.USD","LU2125909247.SGD","LU1035773651.USD","LU1923622614.USD","LU2461242641.AUD","LU2089984988.USD","LU0868494708.USD","BK4559","LU0098860793.USD","LU1057294990.SGD","LU1093756168.USD","LU2357627491.SGD","LU2468319806.SGD","LU1934455277.USD","BK4588","LU1934455863.HKD","LU1037948897.HKD","LU0965509010.AUD","LU0203347892.USD","IE00BJT1NW94.SGD","LU1941712264.USD","LU1116320901.HKD","LU1066051811.HKD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU2361045086.USD","LU2491050071.SGD","IE00BLSP4239.USD","LU2433249047.HKD","MRK","LU0058720904.USD","IE00BBT3K403.USD","LU1989771016.USD","LU0266013472.USD","LU2491049909.HKD","LU1929549753.HKD","LU1699723380.USD","LU0211331839.USD","LU0965508806.USD","LU1983299246.USD","SG9999001440.SGD","IE00B1BXHZ80.USD","LU0985320562.USD","IE00B2B36J28.USD","LU1989772923.USD","LU0265550946.USD","LU1061106388.HKD","LU1291159041.SGD","IE00BSNM7G36.USD","BK4516","SG9999015341.SGD","LU2112291526.USD","LU1037948541.HKD","IE0002141913.USD","LU1941712348.USD","LU0320765489.SGD","LU1934455194.USD","LU0208291251.USD","LU0130517989.USD","LU0980610538.SGD","SG9999014567.USD","IE00BN8TJ469.HKD","LU2360032135.SGD","BK4534","IE000M9KFDE8.USD","LU2361044949.HKD","IE00BJJMRZ35.SGD","LU0320765646.SGD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1066051225.USD","BK4533","BK4007","SG9999014559.SGD","LU2125909593.SGD","LU0106261372.USD","LU1974910355.USD","LU0122379950.USD","LU1162221912.USD","LU2125154935.USD","LU1069347547.HKD","LU0203345920.USD","LU1066053197.SGD","LU2324357040.USD","LU0648001328.SGD","LU0070302665.USD","LU0868494617.USD","BK4550","LU0432979614.USD","LU2361044865.SGD","LU2023250843.SGD","LU0265550359.USD","LU0942090050.USD","LU1571399168.USD","LU2106854487.HKD","LU0130102774.USD","LU0234572021.USD","LU0861579265.USD","LU2023250504.SGD","IE0009355771.USD","SG9999013999.USD","LU1201861249.SGD","SG9999001176.USD","LU1585245621.USD","LU1989772840.SGD","SG9999015358.SGD","SG9999014575.USD","LU1066051498.USD","SGXZ57979304.SGD","IE00BLSP4452.SGD","LU0238689110.USD","LU1917777945.USD","SG9999002232.USD","LU0859254822.USD","LU1116320737.USD","SG9999002224.SGD","LU0965509283.SGD","LU1093756325.SGD","LU2491050154.USD","LU0477156953.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169778338","title":"默沙东Keytruda®联合Padcev®获欧盟CHMP积极意见，用于顺铂不适切可切除肌层浸润性膀胱癌成人围手术期治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1169778338","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169778338?lang=zh_cn&edition=full","pubTime":"2026-05-22 19:56","pubTimestamp":1779451013,"startTime":"0","endTime":"0","summary":"默沙东宣布，其药物Keytruda®（帕博利珠单抗）联合Padcev®（enfortumab vedotin-ejfv）用于治疗顺铂不适切的可切除肌层浸润性膀胱癌成人患者的围手术期治疗方案，已获得欧洲药品管理局人用药品委员会（CHMP）的积极意见。这一进展为治疗方案在欧洲的最终获批铺平了道路，有望为特定膀胱癌患者群体提供一种重要的新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","SG9999014542.SGD","LU2023250504.SGD","LU2491050071.SGD","SG9999014559.SGD","LU0265550946.USD","IE00BFTCPJ56.SGD","SG9999015358.SGD","LU2360032135.SGD","LU2125909247.SGD","SG9999002224.SGD","LU0130517989.USD","LU0965509283.SGD","LU1989772840.SGD","LU2491050154.USD","LU0234572021.USD","LU1571399168.USD","LU0130102774.USD","LU1116320737.USD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU1066051811.HKD","IE000M9KFDE8.USD","LU2125154935.USD","BK4588","SG9999015341.SGD","LU0868494708.USD","LU1941712264.USD","BK4007","LU1093756325.SGD","IE00BBT3K403.USD","SG9999014567.USD","LU1291159041.SGD","LU2089984988.USD","LU2433249047.HKD","SG9999014575.USD","LU1037948897.HKD","LU2361044865.SGD","LU2361045086.USD","LU0106261372.USD","LU1057294990.SGD","MRK","LU2106854487.HKD","LU2125909593.SGD","LU1699723380.USD","SG9999013999.USD","LU0265550359.USD","LU0208291251.USD","LU2461242641.AUD","IE0002141913.USD","LU0098860793.USD","LU0211331839.USD","LU0238689110.USD","LU1023059063.AUD","LU1983299246.USD","LU0058720904.USD","IE00BLSP4239.USD","LU1162221912.USD","LU0203347892.USD","BK4550","LU1989771016.USD","LU2491049909.HKD","LU1934455863.HKD","LU1430594728.SGD","LU1989772923.USD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU0320765646.SGD","LU1035773651.USD","LU1974910355.USD","LU2125154778.USD","LU1066053197.SGD","LU1116320901.HKD","LU2023250843.SGD","LU1066051498.USD","BK4533","BK4516","BK4585","LU0861579265.USD","LU0965508806.USD","LU1941712348.USD","LU0859254822.USD","LU1929549753.HKD","LU1585245621.USD","LU0477156953.USD","LU0965509010.AUD","IE00B2B36J28.USD","LU0320765489.SGD","LU1093756168.USD","BK4534","LU1201861249.SGD","BK4559","LU1069347547.HKD","LU0980610538.SGD","LU1934455277.USD","LU2324357040.USD","SG9999002232.USD","LU0070302665.USD","LU0985320562.USD","LU0868494617.USD","IE0009355771.USD","LU1066051225.USD","LU1934455194.USD","LU0203345920.USD","LU0122379950.USD","LU2361044949.HKD","LU0266013472.USD","IE00BLSP4452.SGD","LU0648001328.SGD","LU1061106388.HKD","LU1923622614.USD","SG9999001440.SGD","LU0289739699.SGD","IE00BN8TJ469.HKD","LU0006306889.USD","LU0965509101.SGD","LU2468319806.SGD","SG9999001176.USD","SG9999001176.SGD","LU1917777945.USD","LU2112291526.USD","LU0942090050.USD","LU2357627491.SGD","SGXZ57979304.SGD","LU1037948541.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113236694","title":"合作方科伦药业肺癌联合疗法达成晚期试验目标，默沙东股价盘前大涨3.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113236694","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113236694?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:10","pubTimestamp":1779444646,"startTime":"0","endTime":"0","summary":"默沙东与其合作伙伴科伦药业共同研发的肺癌联合疗法，已成功达成一项关键晚期临床试验的主要目标。受此积极消息推动，默沙东股价在盘前交易时段应声上涨3.7%。该疗法在晚期试验中展现出的潜力，为后续的监管审批与商业化进程奠定了坚实基础，也提振了市场对该公司肿瘤管线前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2491050154.USD","MRK","LU2125154935.USD","LU1061106388.HKD","IE0009355771.USD","LU0648001328.SGD","LU2125909593.SGD","LU2324357040.USD","SG9999001176.USD","LU0868494617.USD","SG9999001440.SGD","LU2106854487.HKD","LU1934455863.HKD","LU0859254822.USD","LU1585245621.USD","LU0203345920.USD","LU2357627491.SGD","IE00BLSP4452.SGD","LU2125909247.SGD","LU2461242641.AUD","LU0265550359.USD","IE00BFTCPJ56.SGD","BK4588","LU0070302665.USD","LU0965509010.AUD","LU1035773651.USD","LU0320765646.SGD","LU1989772923.USD","SG9999015341.SGD","BK4585","LU0432979614.USD","LU1066053197.SGD","IE00BSNM7G36.USD","LU1066051811.HKD","IE00B2B36J28.USD","IE00BLSP4239.USD","IE00B1BXHZ80.USD","LU1116320901.HKD","LU1923622614.USD","LU0234572021.USD","LU1116320737.USD","SG9999013999.USD","SG9999014559.SGD","LU0098860793.USD","LU0130102774.USD","LU0266013472.USD","SG9999014542.SGD","LU0238689110.USD","LU2468319806.SGD","LU1917777945.USD","LU1162221912.USD","LU1941712264.USD","SG9999014567.USD","LU0208291251.USD","SG9999002224.SGD","LU2361044949.HKD","BK4007","LU2361044865.SGD","LU0965509101.SGD","LU1066051225.USD","LU2023250504.SGD","LU1974910355.USD","LU1069347547.HKD","LU0980610538.SGD","SG9999002232.USD","LU0289739699.SGD","SG9999015358.SGD","BK4534","LU0861579265.USD","SG9999014575.USD","LU1571399168.USD","LU2361045086.USD","LU1037948541.HKD","IE0002141913.USD","LU1989772840.SGD","SG9999001176.SGD","LU0477156953.USD","LU0965508806.USD","LU1023059063.AUD","BK4533","LU1093756168.USD","LU0868494708.USD","LU1989771016.USD","LU1093756325.SGD","LU1983299246.USD","LU2360032135.SGD","SGXZ57979304.SGD","LU0320765489.SGD","LU2023250843.SGD","IE00BJT1NW94.SGD","LU1941712348.USD","LU1934455277.USD","BK4516","LU0965509283.SGD","LU1929549753.HKD","LU1934455194.USD","LU2089984988.USD","LU0006306889.USD","LU1037948897.HKD","LU0058720904.USD","LU1201861249.SGD","IE00BBT3K403.USD","LU1066051498.USD","BK4550","LU0265550946.USD","LU1699723380.USD","LU0203347892.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU0122379950.USD","LU2491050071.SGD","LU2433249047.HKD","LU2491049909.HKD","LU0211331839.USD","LU1430594728.SGD","IE00BN8TJ469.HKD","LU2112291526.USD","LU0942090050.USD","LU1291159041.SGD","IE00B4R5TH58.HKD","LU0106261372.USD","IE000M9KFDE8.USD","LU2125154778.USD","LU0985320562.USD","LU0130517989.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174026782","title":"异动解读｜默沙东盘前上涨3.18%，TROP2 ADC子宫内膜癌III期试验达双重主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1174026782","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174026782?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:46","pubTimestamp":1779443195,"startTime":"0","endTime":"0","summary":"5月22日，默沙东盘前上涨3.18%，报119.61美元/股，成交额50.76万美元。消息面上，默沙东宣布其与科伦博泰合作开发的TROP2靶向抗体偶联药物Sacituzumab Tirumotecan，在针对晚期或复发性子宫内膜癌患者的全球III期TroFuse-005试验中，达到了总生存期与无进展生存期双重主要终点，同时达到客观缓解率次要终点。与医生选择疗法相比，Sac-TMT在两项主要指标上均显示出统计学显著且具有临床意义的改善，安全性与既往研究一致。该数据进一步验证了默沙东在ADC管线上的布局潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146335978","title":"异动解读｜默沙东盘后上涨3.11%，TROP2 ADC子宫内膜癌III期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1146335978","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146335978?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:18","pubTimestamp":1779398316,"startTime":"0","endTime":"0","summary":"5月22日，默沙东盘后上涨3.11%，报119.53美元/股，成交额5342.41万美元。消息面上，默沙东宣布其与科伦博泰合作开发的TROP2靶向抗体偶联药物Sacituzumab Tirumotecan在针对晚期或复发性子宫内膜癌的全球III期TroFuse-005试验中，达到了总生存期与无进展生存期双重主要终点，同时达到客观缓解率次要终点。与医生选择疗法相比，Sac-TMT在两项主要指标上均显示出统计学显著且具有临床意义的改善，安全性与既往研究一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105243252","title":"科伦博泰生物与默沙东联合疗法安全性概览：Sac-TMT联合帕博利珠单抗总体可控，与各组分已知安全性特征一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1105243252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105243252?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:04","pubTimestamp":1779397489,"startTime":"0","endTime":"0","summary":"科伦博泰生物与默沙东联合开发的Sac-TMT与帕博利珠单抗（Pembrolizumab）联合治疗方案，其安全性特征总体而言是可控的。观察到的安全性数据与各单药组分已知的安全性特征保持一致，未出现超出预期的新的安全性信号。这一结果表明，该联合疗法的安全性在临床上处于可管理范畴，为其进一步的临床开发与应用提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051225.USD","LU0196878994.USD","IE0002141913.USD","LU1571399168.USD","LU2324357040.USD","IE00BN8TJ469.HKD","LU2106854487.HKD","LU1069347547.HKD","LU2361044865.SGD","06990","LU1941712264.USD","LU1917777945.USD","LU1923622614.USD","LU0965509101.SGD","LU2023250843.SGD","LU0965509010.AUD","LU1974910355.USD","LU1989772923.USD","LU1291159041.SGD","BK4559","LU0098860793.USD","LU1983299246.USD","LU0070302665.USD","LU0266013472.USD","LU1066053197.SGD","SG9999001176.SGD","IE00B4R5TH58.HKD","LU1066051498.USD","LU0477156953.USD","IE00BSNM7G36.USD","LU0985320562.USD","LU0965509283.SGD","LU1057294990.SGD","LU1093756325.SGD","LU0965508806.USD","LU1061106388.HKD","LU1934455863.HKD","BK4534","LU2361045086.USD","LU1066051811.HKD","SG9999001176.USD","BK4585","LU1093756168.USD","SG9999015341.SGD","LU1934455277.USD","BK4516","MRK","LU2491050071.SGD","LU1430594728.SGD","LU1037948897.HKD","LU1162221912.USD","LU2491050154.USD","LU2468319806.SGD","LU0320765646.SGD","SG9999001440.SGD","LU2023250504.SGD","LU0859254822.USD","BK4007","IE00B1BXHZ80.USD","LU0130517989.USD","SG9999014542.SGD","LU2125154778.USD","SG9999002232.USD","SG9999015358.SGD","LU0058720904.USD","LU0211331839.USD","LU2361044949.HKD","LU0289739699.SGD","LU2125909593.SGD","LU2089984988.USD","LU1699723380.USD","IE00BFTCPJ56.SGD","LU2125909247.SGD","BK1161","LU2125154935.USD","SG9999002224.SGD","LU0238689110.USD","IE000M9KFDE8.USD","LU0203347892.USD","LU0648001328.SGD","LU0980610538.SGD","LU2112291526.USD","LU1934455194.USD","SG9999013999.USD","LU1941712348.USD","LU2491049909.HKD","LU0265550359.USD","LU0868494708.USD","LU0868494617.USD","LU1035773651.USD","LU0106261372.USD","IE0009355771.USD","LU1037948541.HKD","LU0861579265.USD","LU0432979614.USD","LU1023059063.AUD","LU0130102774.USD","LU0208291251.USD","IE00B2B36J28.USD","BK4533","LU0203345920.USD","SGXZ57979304.SGD","SG9999014575.USD","LU0320765489.SGD","LU2433249047.HKD","LU1201861249.SGD","LU0006306889.USD","SG9999014567.USD","LU1116320737.USD","IE00BLSP4452.SGD","LU2357627491.SGD","IE00BBT3K403.USD","LU2360032135.SGD","LU1585245621.USD","IE00BLSP4239.USD","IE00BJJMRZ35.SGD","BK4588","SG9999014559.SGD","LU2461242641.AUD","LU0265550946.USD","IE00BJT1NW94.SGD","LU0942090050.USD","LU1929549753.HKD","BK4550","LU1989772840.SGD","LU1989771016.USD","LU0234572021.USD","LU1116320901.HKD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637780378","title":"港股异动 | 科伦博泰生物(06990)涨超5% 与默沙东合作的TROP2 ADC全球III期研究达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2637780378","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637780378?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:58","pubTimestamp":1779332292,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超5%，截至发稿，涨3.3%，报451.4港元，成交额1.66亿港元。消息面上，近日，据科伦博泰生物官微消息，默沙东宣布，与公司合作开发的在研TROP2靶向抗体药物偶联物sacituzumab tirumotecan，在针对某些晚期或复发性子宫内膜癌患者的关键性III期TroFuse-005试验中，达到了总生存期和无进展生存期的主要终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1066051225.USD","SG9999001440.SGD","LU0965509101.SGD","LU0058720904.USD","SG9999014559.SGD","SG9999015358.SGD","SG9999015341.SGD","LU1934455277.USD","BK4534","LU2361044949.HKD","SG9999014542.SGD","IE00B4R5TH58.HKD","LU2433249047.HKD","LU0985320562.USD","SG9999014567.USD","BK4516","LU0320765489.SGD","BK4533","LU0208291251.USD","LU2106854487.HKD","LU0868494617.USD","LU0965509010.AUD","BK4559","LU1037948897.HKD","SG9999001176.SGD","LU2023250504.SGD","BK1161","LU1585245621.USD","LU1069347547.HKD","LU1291159041.SGD","LU0203345920.USD","IE0002141913.USD","SG9999013999.USD","LU2324357040.USD","LU1934455194.USD","LU0868494708.USD","SGXZ57979304.SGD","LU1116320901.HKD","LU1989772923.USD","LU1571399168.USD","LU2125909247.SGD","BK4550","LU0211331839.USD","LU2125909593.SGD","LU0106261372.USD","LU1066051498.USD","LU0861579265.USD","LU2491050071.SGD","LU1941712348.USD","LU1923622614.USD","SG9999001176.USD","LU0432979614.USD","LU1941712264.USD","IE00BLSP4452.SGD","IE0009355771.USD","IE00BN8TJ469.HKD","LU1201861249.SGD","LU1974910355.USD","LU2361044865.SGD","BK4134","LU1162221912.USD","BK4080","LU1093756168.USD","IE00B2B36J28.USD","LU2491050154.USD","SG9999014575.USD","LU0006306889.USD","LU0203347892.USD","LU1989771016.USD","LU1035773651.USD","LU1934455863.HKD","LU2023250843.SGD","LU2360032135.SGD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU0289739699.SGD","LU1917777945.USD","LU1037948541.HKD","LU1699723380.USD","SG9999002232.USD","BK4585","LU0477156953.USD","IE00BJJMRZ35.SGD","LU0265550359.USD","LU0320765646.SGD","LU1066053197.SGD","LU0965509283.SGD","LU0238689110.USD","IE00B1BXHZ80.USD","LU0648001328.SGD","LU1057294990.SGD","IE00BLSP4239.USD","BK4588","MRK","IE000M9KFDE8.USD","LU0196878994.USD","LU1061106388.HKD","LU2461242641.AUD","LU1929549753.HKD","LU1066051811.HKD","LU0942090050.USD","LU0965508806.USD","LU2125154935.USD","LU1983299246.USD","LU1989772840.SGD","IE00BBT3K403.USD","IE00BSNM7G36.USD","LU2491049909.HKD","LU0098860793.USD","06990","LU1093756325.SGD","LU2125154778.USD","LU1430594728.SGD","SG9999002224.SGD","IE00BJT1NW94.SGD","LU0130102774.USD","LU2089984988.USD","LU0980610538.SGD","LU1023059063.AUD","LU0070302665.USD","LU0122379950.USD","BK4231","LU0265550946.USD","LU0859254822.USD","BK4007","LU2361045086.USD","LU0266013472.USD","LU2357627491.SGD","LU1116320737.USD","LU2112291526.USD","LU2468319806.SGD","LU0130517989.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182393564","title":"国家广告审查委员会就Bravecto Quantum剂量宣称问题 将默沙东动物保健部门提交FTC及FDA处理","url":"https://stock-news.laohu8.com/highlight/detail?id=1182393564","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182393564?lang=zh_cn&edition=full","pubTime":"2026-05-20 23:03","pubTimestamp":1779289387,"startTime":"0","endTime":"0","summary":"国家广告审查委员会已决定，将默沙东（Merck）旗下动物保健部门关于其产品Bravecto Quantum的剂量相关宣传主张，提交给美国联邦贸易委员会（FTC）及美国食品药品监督管理局（FDA）进行进一步审查与处理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2461242641.AUD","SGXZ57979304.SGD","SG9999014559.SGD","LU1037948897.HKD","LU1585245621.USD","LU2491050071.SGD","LU0477156953.USD","LU0289739699.SGD","LU2023250504.SGD","LU0130102774.USD","LU0985320562.USD","LU2125154778.USD","IE0002141913.USD","SG9999001440.SGD","BK4550","LU1934455277.USD","BK4533","BK4559","LU0130517989.USD","LU1934455863.HKD","LU1201861249.SGD","SG9999014567.USD","LU2106854487.HKD","IE00B4R5TH58.HKD","LU0070302665.USD","LU1162221912.USD","LU2361045086.USD","BK4534","BK4516","LU2433249047.HKD","LU0965509010.AUD","LU0238689110.USD","LU2112291526.USD","LU0265550946.USD","LU1929549753.HKD","LU1066051498.USD","LU1430594728.SGD","LU1035773651.USD","LU1699723380.USD","LU0980610538.SGD","IE00B1BXHZ80.USD","LU1983299246.USD","LU2491049909.HKD","SG9999002232.USD","LU2361044949.HKD","LU1974910355.USD","IE000M9KFDE8.USD","LU1941712348.USD","LU0861579265.USD","LU0942090050.USD","LU1291159041.SGD","BK4007","IE00BLSP4239.USD","LU1934455194.USD","LU1116320737.USD","LU0868494617.USD","LU1066051811.HKD","IE00BLSP4452.SGD","LU1093756325.SGD","LU2089984988.USD","IE00BBT3K403.USD","LU0211331839.USD","SG9999014542.SGD","LU2023250843.SGD","LU0122379950.USD","SG9999002224.SGD","LU0965508806.USD","SG9999001176.USD","LU1571399168.USD","SG9999015341.SGD","LU0006306889.USD","BK4585","LU0203345920.USD","LU0432979614.USD","LU0965509283.SGD","LU1069347547.HKD","LU2491050154.USD","LU1917777945.USD","LU1057294990.SGD","LU1061106388.HKD","IE00B2B36J28.USD","LU2357627491.SGD","LU2125909593.SGD","IE00BFTCPJ56.SGD","MRK","LU1989772840.SGD","LU2361044865.SGD","IE0009355771.USD","LU2125909247.SGD","SG9999015358.SGD","LU2468319806.SGD","BK4588","SG9999013999.USD","LU0320765489.SGD","LU0265550359.USD","LU0859254822.USD","LU1066051225.USD","LU0208291251.USD","LU1989771016.USD","LU1989772923.USD","LU0965509101.SGD","IE00BJT1NW94.SGD","LU2125154935.USD","LU1093756168.USD","LU1037948541.HKD","LU1116320901.HKD","LU1066053197.SGD","LU0320765646.SGD","IE00BN8TJ469.HKD","SG9999001176.SGD","LU1923622614.USD","LU0203347892.USD","LU2360032135.SGD","SG9999014575.USD","IE00BSNM7G36.USD","LU0098860793.USD","LU0648001328.SGD","LU2324357040.USD","LU0868494708.USD","LU0266013472.USD","LU1941712264.USD","LU0234572021.USD","LU1023059063.AUD","LU0106261372.USD","LU0058720904.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140623873","title":"世卫组织驻刚果代表：默沙东Ervebo是潜在可预防埃博拉病毒的疫苗之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1140623873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140623873?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:58","pubTimestamp":1779184699,"startTime":"0","endTime":"0","summary":"世界卫生组织驻刚果（金）代表指出，默沙东公司研发的Ervebo疫苗，属于有望为埃博拉病毒提供预防与保护的潜在候选疫苗之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948897.HKD","LU1162221912.USD","LU1116320737.USD","LU1069347547.HKD","IE00BSNM7G36.USD","LU0868494617.USD","LU2125154935.USD","BK4588","IE00BN8TJ469.HKD","LU2491049909.HKD","LU0965509101.SGD","LU0106261372.USD","SG9999014567.USD","IE00BLSP4452.SGD","LU0058720904.USD","LU2023250504.SGD","LU0070302665.USD","LU1923622614.USD","LU2360032135.SGD","LU1116320901.HKD","LU0266013472.USD","IE00BBT3K403.USD","SG9999001176.USD","BK4007","LU1066051225.USD","SG9999015341.SGD","LU0320765646.SGD","LU2125909593.SGD","LU1066053197.SGD","SGXZ57979304.SGD","LU0985320562.USD","LU2125154778.USD","LU0130517989.USD","LU2361044949.HKD","BK4550","BK4585","LU0006306889.USD","LU1201861249.SGD","LU0208291251.USD","LU1934455863.HKD","SG9999001440.SGD","LU1291159041.SGD","LU0965509283.SGD","SG9999014559.SGD","LU2491050071.SGD","LU1023059063.AUD","LU1066051498.USD","LU0320765489.SGD","LU0289739699.SGD","LU0265550359.USD","SG9999001176.SGD","LU1989771016.USD","LU1585245621.USD","LU2461242641.AUD","LU0868494708.USD","LU2112291526.USD","IE00B2B36J28.USD","LU0965508806.USD","LU1430594728.SGD","BK4533","IE00BJJMRZ35.SGD","LU0203345920.USD","LU1917777945.USD","LU0648001328.SGD","MRK","BK4534","LU2491050154.USD","SG9999015358.SGD","LU1941712348.USD","LU0238689110.USD","LU1934455194.USD","LU0122379950.USD","LU1983299246.USD","LU2468319806.SGD","LU1093756325.SGD","LU1699723380.USD","LU0234572021.USD","IE00B4R5TH58.HKD","LU2361045086.USD","LU2324357040.USD","LU1061106388.HKD","LU0861579265.USD","BK4559","LU0265550946.USD","IE0002141913.USD","LU0980610538.SGD","LU0098860793.USD","LU0859254822.USD","LU1035773651.USD","LU1066051811.HKD","LU2433249047.HKD","SG9999002232.USD","IE00B1BXHZ80.USD","IE00BFTCPJ56.SGD","LU0965509010.AUD","LU1989772923.USD","LU0130102774.USD","SG9999014575.USD","IE00BLSP4239.USD","LU0477156953.USD","LU1941712264.USD","LU1934455277.USD","LU1929549753.HKD","LU1989772840.SGD","LU2125909247.SGD","LU0942090050.USD","LU2357627491.SGD","SG9999002224.SGD","LU0203347892.USD","IE00BJT1NW94.SGD","LU1571399168.USD","IE0009355771.USD","LU2089984988.USD","SG9999014542.SGD","LU2361044865.SGD","LU0432979614.USD","LU0211331839.USD","LU1093756168.USD","SG9999013999.USD","LU1974910355.USD","LU2106854487.HKD","LU1057294990.SGD","BK4516","LU1037948541.HKD","LU2023250843.SGD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636006648","title":"默沙东ADC癌症新药再下一城，子宫内膜癌III期研究大获成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2636006648","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636006648?lang=zh_cn&edition=full","pubTime":"2026-05-19 03:46","pubTimestamp":1779133560,"startTime":"0","endTime":"0","summary":"　　默沙东与科伦博泰近日宣布，其合作开发的TROP2靶向抗体偶联药物Sac-TMT在III期TroFuse-005试验中取得积极结果。该研究针对的是已经接受过铂类化疗和免疫治疗后病情进展的晚期或复发性子宫内膜癌患者，这也是当前治疗选择非常有限的难治人群。　　TroFuse-005是默沙东围绕Sac-TMT搭建的大型临床开发项目——TroFuse计划中的首个成功读出III期数据的研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-19/doc-inhykhiz7760343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0965509010.AUD","LU0320765646.SGD","LU0477156953.USD","LU1162221912.USD","LU1989771016.USD","LU0289739699.SGD","SGXZ57979304.SGD","LU0965509283.SGD","IE00BJJMRZ35.SGD","LU1974910355.USD","BK4585","LU2461242641.AUD","LU1917777945.USD","SG9999001176.USD","BK4588","LU0130517989.USD","LU2491050154.USD","LU1069347547.HKD","SG9999014567.USD","LU1941712264.USD","IE0009355771.USD","LU1201861249.SGD","LU1035773651.USD","LU0130102774.USD","LU1923622614.USD","LU2106854487.HKD","LU1585245621.USD","IE00BFTCPJ56.SGD","LU1430594728.SGD","LU1037948897.HKD","LU0070302665.USD","LU1093756325.SGD","LU1116320737.USD","LU0432979614.USD","SG9999001440.SGD","LU0203347892.USD","LU0234572021.USD","LU1066051225.USD","LU1061106388.HKD","LU0265550359.USD","LU1057294990.SGD","LU0265550946.USD","SG9999013999.USD","LU1934455277.USD","LU0942090050.USD","LU2089984988.USD","SG9999015358.SGD","LU2468319806.SGD","LU0868494617.USD","LU0006306889.USD","LU1989772923.USD","LU0208291251.USD","LU1093756168.USD","BK4534","LU2361045086.USD","LU2125909593.SGD","LU0266013472.USD","IE00BJT1NW94.SGD","LU2361044949.HKD","IE0002141913.USD","LU1291159041.SGD","LU2125909247.SGD","LU1571399168.USD","BK4231","LU0648001328.SGD","SG9999014575.USD","LU0211331839.USD","LU1934455863.HKD","LU2491050071.SGD","IE00BLSP4452.SGD","SG9999014542.SGD","IE00B2B36J28.USD","LU1989772840.SGD","MRK","IE00BSNM7G36.USD","LU0106261372.USD","LU0238689110.USD","LU2491049909.HKD","IE00B4R5TH58.HKD","LU1699723380.USD","LU0861579265.USD","LU2125154778.USD","LU1116320901.HKD","LU1066051498.USD","IE00BBT3K403.USD","SG9999002232.USD","LU1023059063.AUD","LU1929549753.HKD","LU0965508806.USD","LU1934455194.USD","IE00B1BXHZ80.USD","BK4533","LU0868494708.USD","LU0980610538.SGD","LU1941712348.USD","BK4516","IE000M9KFDE8.USD","LU0320765489.SGD","LU2023250843.SGD","LU0965509101.SGD","BK4134","SG9999001176.SGD","BK4007","LU2023250504.SGD","BK4559","LU2433249047.HKD","IE00BLSP4239.USD","LU1037948541.HKD","LU2361044865.SGD","LU0098860793.USD","SG9999002224.SGD","LU2357627491.SGD","LU2360032135.SGD","LU1066051811.HKD","LU1983299246.USD","LU0058720904.USD","LU0859254822.USD","LU0203345920.USD","IE00BN8TJ469.HKD","LU0985320562.USD","LU2112291526.USD","LU2324357040.USD","LU1066053197.SGD","SG9999014559.SGD","LU2125154935.USD","BK4080","SG9999015341.SGD","LU0122379950.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143607187","title":"默沙东宣布TROFUSE-005试验评估Sacituzumab Tirumotecan在特定晚期或复发性子宫内膜癌患者中达到总生存期与无进展生存期主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1143607187","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143607187?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:03","pubTimestamp":1779102198,"startTime":"0","endTime":"0","summary":"默沙东公司宣布，其TROFUSE-005试验评估Sacituzumab Tirumotecan（Sac-TMT）在特定晚期或复发性子宫内膜癌患者中，达到了总生存期和无进展生存期的主要终点。该药物的安全性特征与既往研究报告中所观察到的情况保持一致。\n与医生选择的治疗方案相比，Sac-TMT在总生存期和无进展生存期方面均显示出统计学上显著且具有临床意义的改善。此外，该研究也达到了其关键的次要终点——客观缓解率。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","LU2491050154.USD","LU0234572021.USD","LU2125909247.SGD","LU0098860793.USD","BK4550","LU1934455194.USD","LU0122379950.USD","LU0320765489.SGD","IE00B1BXHZ80.USD","IE0009355771.USD","LU1093756168.USD","LU1066051498.USD","BK4007","LU2106854487.HKD","LU0868494708.USD","BK4588","LU0965509010.AUD","LU0208291251.USD","LU0648001328.SGD","LU1934455277.USD","LU0130102774.USD","LU0265550359.USD","LU1023059063.AUD","LU2023250504.SGD","BK4559","LU0058720904.USD","LU0868494617.USD","LU2491050071.SGD","LU1923622614.USD","SG9999014542.SGD","IE00BJT1NW94.SGD","LU2491049909.HKD","LU2324357040.USD","LU1941712264.USD","LU1917777945.USD","LU1430594728.SGD","LU2361044865.SGD","LU0942090050.USD","IE00BFTCPJ56.SGD","LU2125154778.USD","LU2361044949.HKD","LU1035773651.USD","LU1989771016.USD","LU0859254822.USD","LU2357627491.SGD","LU2023250843.SGD","LU1116320737.USD","SG9999002232.USD","LU2125154935.USD","IE00BSNM7G36.USD","LU0432979614.USD","LU1037948897.HKD","BK4516","LU1934455863.HKD","IE00BN8TJ469.HKD","LU1162221912.USD","LU1941712348.USD","BK4585","LU0965509283.SGD","SG9999015341.SGD","LU0289739699.SGD","LU1069347547.HKD","SG9999001176.SGD","LU0266013472.USD","IE00B2B36J28.USD","LU2125909593.SGD","LU2112291526.USD","SG9999001176.USD","SG9999001440.SGD","LU0320765646.SGD","SG9999013999.USD","LU1571399168.USD","SG9999014559.SGD","IE00B4R5TH58.HKD","LU1066053197.SGD","IE0002141913.USD","SGXZ57979304.SGD","LU1061106388.HKD","LU1201861249.SGD","LU1066051811.HKD","IE00BBT3K403.USD","LU0070302665.USD","LU1989772840.SGD","IE000M9KFDE8.USD","SG9999014567.USD","LU0238689110.USD","LU2089984988.USD","LU2361045086.USD","SG9999015358.SGD","LU1093756325.SGD","LU0965508806.USD","LU1291159041.SGD","LU0265550946.USD","SG9999002224.SGD","LU0861579265.USD","BK4534","LU1974910355.USD","LU0965509101.SGD","LU2468319806.SGD","SG9999014575.USD","LU2461242641.AUD","LU0203347892.USD","IE00BLSP4452.SGD","LU2433249047.HKD","LU1989772923.USD","LU1699723380.USD","LU1116320901.HKD","LU1057294990.SGD","LU0106261372.USD","LU1037948541.HKD","LU1983299246.USD","LU0980610538.SGD","LU0006306889.USD","LU1585245621.USD","LU0130517989.USD","LU1929549753.HKD","IE00BJJMRZ35.SGD","LU0477156953.USD","LU0203345920.USD","LU0985320562.USD","LU1066051225.USD","IE00BLSP4239.USD","LU2360032135.SGD","MRK","BK4533"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.merck.com","stockEarnings":[{"period":"1week","weight":0.048},{"period":"1month","weight":0.0699},{"period":"3month","weight":-0.0224},{"period":"6month","weight":0.1442},{"period":"1year","weight":0.5432},{"period":"ytd","weight":0.1374}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0513},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1043},{"period":"1year","weight":0.2961},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"默克制药公司于1970年在新泽西州注册成立。该公司是一家全球医疗保健公司，通过其处方药提供创新的健康解决方案，包括生物疗法、疫苗和动物保健产品。该公司的营运主要以产品为基础进行管理，包括两个经营分部：制药及动物保健国际。","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.010352},{"month":2,"riseRate":0.456522,"avgChangeRate":0.000847},{"month":3,"riseRate":0.608696,"avgChangeRate":-0.003426},{"month":4,"riseRate":0.595745,"avgChangeRate":0.014758},{"month":5,"riseRate":0.638298,"avgChangeRate":0.017888},{"month":6,"riseRate":0.521739,"avgChangeRate":0.013031},{"month":7,"riseRate":0.478261,"avgChangeRate":0.003083},{"month":8,"riseRate":0.5,"avgChangeRate":0.00331},{"month":9,"riseRate":0.521739,"avgChangeRate":-0.006239},{"month":10,"riseRate":0.543478,"avgChangeRate":0.018718},{"month":11,"riseRate":0.717391,"avgChangeRate":0.032717},{"month":12,"riseRate":0.608696,"avgChangeRate":0.013778}],"exchange":"NYSE","name":"默沙东","nameEN":"Merck"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供默沙东(MRK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"默沙东,MRK,默沙东股票,默沙东股票老虎,默沙东股票老虎国际,默沙东行情,默沙东股票行情,默沙东股价,默沙东股市,默沙东股票价格,默沙东股票交易,默沙东股票购买,默沙东股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供默沙东(MRK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}